| Discovery and mechanism of highly efficient cyclic cell-penetrating peptides Z Qian, A Martyna, RL Hard, J Wang, G Appiah-Kubi, C Coss, MA Phelps, ... Biochemistry 55 (18), 2601-2612, 2016 | 298 | 2016 |
| Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit ML Mohler, CE Bohl, A Jones, CC Coss, R Narayanan, Y He, DJ Hwang, ... Journal of medicinal chemistry 52 (12), 3597-3617, 2009 | 248 | 2009 |
| Development of selective androgen receptor modulators (SARMs) R Narayanan, CC Coss, JT Dalton Molecular and cellular endocrinology 465, 134-142, 2018 | 233 | 2018 |
| Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats W Gao, PJ Reiser, CC Coss, MA Phelps, JD Kearbey, DD Miller, ... Endocrinology 146 (11), 4887-4897, 2005 | 233 | 2005 |
| Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling … R Narayanan, CC Coss, M Yepuru, JD Kearbey, DD Miller, JT Dalton Molecular Endocrinology 22 (11), 2448-2465, 2008 | 84 | 2008 |
| Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer S Ponnusamy, CC Coss, T Thiyagarajan, K Watts, DJ Hwang, Y He, ... Cancer Research 77 (22), 6282-6298, 2017 | 83 | 2017 |
| Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-Hodgkin lymphoma BK Harrington, HL Gardner, R Izumi, A Hamdy, W Rothbaum, ... PLoS One 11 (7), e0159607, 2016 | 66 | 2016 |
| SUV39H1 represses the expression of cytotoxic T-lymphocyte effector genes to promote colon tumor immune evasion C Lu, D Yang, JD Klement, IK Oh, NM Savage, JL Waller, AH Colby, ... Cancer immunology research 7 (3), 414-427, 2019 | 50 | 2019 |
| A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T-and B-cell lymphomas DW Sborov, A Canella, EM Hade, X Mo, S Khountham, J Wang, W Ni, ... Leukemia & lymphoma 58 (10), 2310-2318, 2017 | 50 | 2017 |
| Cancer cachexia therapy: a key weapon in the fight against cancer CC Coss, CE Bohl, JT Dalton Current Opinion in Clinical Nutrition & Metabolic Care 14 (3), 268-273, 2011 | 43 | 2011 |
| Androgen receptor antagonists: a patent review (2008–2011) ML Mohler, CC Coss, CB Duke III, SA Patil, DD Miller, JT Dalton Expert opinion on therapeutic patents 22 (5), 541-565, 2012 | 42 | 2012 |
| CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128 M Badawi, J Kim, A Dauki, D Sutaria, T Motiwala, R Reyes, N Wani, ... Oncotarget 9 (40), 26032, 2018 | 36 | 2018 |
| Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer CC Coss, A Jones, JT Dalton Steroids 90, 94-100, 2014 | 36 | 2014 |
| Transcriptionally active androgen receptor splice variants promote hepatocellular carcinoma progression AM Dauki, JS Blachly, EA Kautto, S Ezzat, MH Abdel-Rahman, CC Coss Cancer research 80 (3), 561-575, 2020 | 34 | 2020 |
| Phyllanthusmin derivatives induce apoptosis and reduce tumor burden in high-grade serous ovarian cancer by late-stage autophagy inhibition AN Young, D Herrera, AC Huntsman, MA Korkmaz, DD Lantvit, ... Molecular cancer therapeutics 17 (10), 2123-2135, 2018 | 33 | 2018 |
| Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs M Phelps, C Coss, H Wang, M Cook, ... Elife 5, 344-357, 2016 | 32 | 2016 |
| The role of malnutrition and muscle wasting in advanced lung cancer R Jain, C Coss, P Whooley, M Phelps, DH Owen Current oncology reports 22, 1-10, 2020 | 30 | 2020 |
| Selective androgen receptor modulators for the treatment of late onset male hypogonadism CC Coss, A Jones, ML Hancock, MS Steiner, JT Dalton Asian journal of andrology 16 (2), 256-261, 2014 | 30 | 2014 |
| Estrogen receptor β selective nonsteroidal estrogens: seeking clinical indications ML Mohler, R Narayanan, CC Coss, K Hu, Y He, Z Wu, SS Hong, ... Expert opinion on therapeutic patents 20 (4), 507-534, 2010 | 30 | 2010 |
| Cachectic cancer patients: immune to checkpoint inhibitor therapy? CC Coss, SK Clinton, MA Phelps Clinical Cancer Research 24 (23), 5787-5789, 2018 | 29 | 2018 |
